GYRE THERAPEUTICS, INC.

GYRESEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1124105

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$105.8M	$113.5M	$102.3M	—	$20.9M
Cost of Goods and Services Sold	$3.9M	$4.6M	$4.8M	—	—
Gross Profit	—	$108.8M	$97.5M	—	—
Research and Development Expense	$12.0M	$13.8M	—	—	$53.0M
Operating Expenses	$89.6M	$176.0M	$88.3M	$95.2M	$78.3M
Operating Income (Loss)	$16.2M	-$67.2M	$9.2M	-$87.9M	-$57.4M
Interest Expense	—	—	—	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$125.4M	$116.5M	$84.8M	$55.7M	$94.8M
Assets, Current	$64.8M	$57.2M	$49.7M	$51.5M	$89.5M
Cash and Cash Equivalents, at Carrying Value	$11.8M	$33.5M	$25.2M	$44.3M	$30.4M
Accounts Receivable, after Allowance for Credit Loss, Current	$19.6M	$15.2M	—	—	$3.3M
Inventory, Net	—	$4.3M	$6.1M	—	—
Liabilities	$27.0M	$38.1M	$12.5M	$14.6M	$18.8M
Liabilities, Current	$19.5M	$20.0M	$12.2M	$14.2M	$17.8M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$3.6M	$25.9M	$10.7M	-$83.8M	-$55.0M
Net Cash Provided by (Used in) Investing Activities	-$19.9M	-$19.8M	-$13.8M	$48.2M	$9.7M
Net Cash Provided by (Used in) Financing Activities	$2.1M	$2.5M	$2.5M	$49.6M	$60.4M
Payments to Acquire Property, Plant, and Equipment	$2.3M	$8.5M	$5.0M	$839.0K	—
Payments of Dividends	—	—	—	$45.0M	—
Payments for Repurchase of Common Stock	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)